Baseline patient demographics, disease characteristics, and prior treatment
| Variable . | All patients (N = 60)23 . | All patients in LTE (n = 16)∗ . |
|---|---|---|
| Age, median (range), y | 50 (19-74) | 49 (22-65) |
| Female, n (%) | 34 (57) | 9 (56) |
| Platelet count at LTE entry, median (range), ×109/L | N/A | 87 (16-321) |
| Duration of ITP, median (range), y | 6.3 (0.4-52.5) | 4.3 (0.5-18.4) |
| No. of unique prior ITP therapies, median (range)† | 4 (1-17) | 3 (1-9) |
| Prior splenectomy, n (%) | 15 (25) | 3 (19) |
| No. of failed prior ITP therapies, median (range)‡ | 1 (0-11) | 1 (0-3) |
| Rilzabrutinib monotherapy, n (%) | 20 (33) | 5 (31) |
| Concomitant ITP medication, n (%) | 40 (67) | 11 (69) |
| CS | 16 (27) | 7 (44) |
| TPO-RA | 17 (28) | 2 (13) |
| CS + TPO-RA | 7 (12) | 2 (13) |
| Variable . | All patients (N = 60)23 . | All patients in LTE (n = 16)∗ . |
|---|---|---|
| Age, median (range), y | 50 (19-74) | 49 (22-65) |
| Female, n (%) | 34 (57) | 9 (56) |
| Platelet count at LTE entry, median (range), ×109/L | N/A | 87 (16-321) |
| Duration of ITP, median (range), y | 6.3 (0.4-52.5) | 4.3 (0.5-18.4) |
| No. of unique prior ITP therapies, median (range)† | 4 (1-17) | 3 (1-9) |
| Prior splenectomy, n (%) | 15 (25) | 3 (19) |
| No. of failed prior ITP therapies, median (range)‡ | 1 (0-11) | 1 (0-3) |
| Rilzabrutinib monotherapy, n (%) | 20 (33) | 5 (31) |
| Concomitant ITP medication, n (%) | 40 (67) | 11 (69) |
| CS | 16 (27) | 7 (44) |
| TPO-RA | 17 (28) | 2 (13) |
| CS + TPO-RA | 7 (12) | 2 (13) |
N/A, not applicable.
Data were collected before entering LTE.
Unique ITP therapies were identified using the standardized generic medication name, and splenectomy was counted as 1 prior ITP therapy.
The number of failed prior ITP therapies was based on the latest record with no response. Only records with nonmissing “was response achieved?” were included. Splenectomy was not included.